It depends on the standard you follow. As of September 2026, BridgeBio Pharma, Inc. (BBIO) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 17.5% / 30% · (Cash+Inv) / Mkt Cap (36m) 11.2% / 30% · Interest income / Revenue 3.71% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 17.5% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 10.9% / 33% · Receivables / Mkt Cap (36m) 2.65% / 49% · Interest income / Revenue 3.71% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 17.5% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 10.9% / 33.33% · Receivables / Mkt Cap (24m) 2.65% / 33.33% · Interest income / Revenue 3.71% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 194.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 66.6% / 33.33% · Receivables / Avg Assets (4Q) 17.1% / 33.33% · Interest income / Revenue 3.71% / 5% | Fail |
| FTSE | Debt / Total Assets 114.6% / 33.33% · (Cash+ST Inv) / Total Assets 71.2% / 33.33% · (Cash+Recv) / Total Assets 88.5% / 33.33% · Interest income / Revenue 3.71% / 5% | Fail |
It depends on the standard you follow. As of September 2026, BridgeBio Pharma, Inc. (BBIO) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. BridgeBio Pharma, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 3.71% of each dividend: BridgeBio Pharma, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a Healthcare company (Biotechnology) with a market capitalization of $15.1B. The Maz Rating grades it against the other companies in its sector.
BridgeBio Pharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $77.36, BridgeBio Pharma, Inc. trades at 15.9x sales. Over the last twelve months it generated about $946M of revenue and a net loss of $592M. It runs a gross margin of 93.5%, an operating margin of -43.4% and a net margin of -60.3%. It shows return on equity of 26.8%, return on invested capital of -23.6% and a free cash flow yield of -2.5%. On the balance sheet: a debt-to-equity ratio of -1.50 and a current ratio of 2.09. Over the past 52 weeks the share price ranged from $62.50 to $93.42, with a beta of 0.97.
BridgeBio Pharma, Inc. does not currently pay a dividend.
28 Wall Street analyst ratings cover the stock: 25 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.